Key points for investors:
- Strong financial performance: FY2025 record revenue ~AUD 260M (≈4x prior year), statutory NPAT ~AUD 3.5M and underlying PBT ~AUD 33M. Operating cash generation strong (AUD 15.9M net cash from operations) and cash balance >AUD 200M.
- Large and growing pipeline: Pipeline increased from AUD 2.1B to AUD 2.3B (~295 deals), including ~18 deals >AUD 30M and a single large European opportunity ~AUD 750M. Management believes they can deliver large contracts in batches (potentially <9 months if accelerated).
- SaaS and margin strategy: Management targets SaaS increasing from ~5–7% today to >30% of revenue over five years via multiple SaaS streams (device-level, sensor/camera/radar SaaS, C2/site and Enterprise C2). Normalized gross margin guidance ~65% (CFO), with system sales (radars/cameras) lowering margins vs dismounted products.
- Manufacturing and supply: Investing in scale—new ERP, 3,000 m2 Sydney facility and planned U.S./EU manufacturing hubs—to expand production from ~AUD 500M p.a. to AUD 2.4B capability. Inventory at FY-end ~AUD 79M (AUD 26M finished goods, AUD 53M raw/long-lead) and FY25 inventory impairment ~AUD 10.3M (largely DroneGun product mix). Management expects to hold long-lead items rather than pure JIT due to long component lead times.
- Market positioning & go-to-market: Broad product mix (RfPatrol, DroneSentry-X, DroneGun, DroneSentry-C2) with ~95% exports and customers across NATO, Europe, U.S., Asia Pacific. Focus on military, border security and growing public safety/civilian verticals (airports, data centers). Emphasis on integration with partners/primes and non-ITAR-friendly positioning.
- Risks & operational priorities: Competitive/technology risk managed via heavy R&D investment (~AUD 70M+ p.a.) and large engineering headcount (350+ engineers). Governance improvements enacted after media scrutiny (retained Tier 1 advisors). Key near-term execution items include converting pipeline deals, scaling manufacturing, rolling out next-gen hardware/software H2/2026–2027, and expanding SaaS uptake and recurring revenues.
- Capital allocation & cost base: Fixed cash costs guided at ~AUD 150M for the year, R&D capitalization planned AUD 25–30M. CFO did not provide a specific FY26 net margin projection but emphasized focus on revenue growth while controlling costs to improve net profitability over time.
Sign In
Buy DRSHF
